C
24.60
0.06 (0.24%)
| Previous Close | 24.54 |
| Open | 24.58 |
| Volume | 152,777 |
| Avg. Volume (3M) | 1,066,605 |
| Market Cap | 1,632,067,328 |
| Price / Sales | 149.31 |
| Price / Book | 2.07 |
| 52 Weeks Range | |
| Earnings Date | 24 Feb 2025 - 28 Feb 2025 |
| Operating Margin (TTM) | -1,633.53% |
| Diluted EPS (TTM) | -2.58 |
| Quarterly Revenue Growth (YOY) | 110.30% |
| Total Debt/Equity (MRQ) | 0.39% |
| Current Ratio (MRQ) | 24.27 |
| Operating Cash Flow (TTM) | -157.84 M |
| Levered Free Cash Flow (TTM) | -83.73 M |
| Return on Assets (TTM) | -19.73% |
| Return on Equity (TTM) | -29.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Celldex Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
1.4
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 1.38 |
|
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.30% |
| % Held by Institutions | 108.05% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 225.20%) | Buy |
| Median | 73.50 (198.78%) | |
| Low | 67.00 (Cantor Fitzgerald, 172.36%) | Buy |
| Average | 73.50 (198.78%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 25.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 29 Jan 2025 | 67.00 (172.36%) | Buy | 25.51 |
| 02 Jan 2025 | 67.00 (172.36%) | Buy | 25.79 | |
| HC Wainwright & Co. | 20 Dec 2024 | 80.00 (225.20%) | Buy | 25.14 |
| 19 Dec 2024 | 80.00 (225.20%) | Buy | 25.38 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Dec 2024 | Announcement | Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis |
| 20 Nov 2024 | Announcement | Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases |
| 11 Nov 2024 | Announcement | Celldex Therapeutics to Present at Upcoming Investor Conferences |
| 06 Nov 2024 | Announcement | Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |